Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Experimental Vaccine Could Help Tackle Opioid Crisis

By Kenny Walter | December 18, 2017

Dr. Gary Matyas’ lab at the Walter Reed Army Institute of Research. Credit MHRP

A new vaccine may be effective in combating the growing opioid problem plaguing the nation.

Researchers from the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) have found that an experimental heroin vaccine induced antibodies that prevented the drug from crossing the blood-brain barrier in mice and rats.

“By eliciting antibodies that bind with heroin in the blood, the vaccine aims to block the euphoria and addictive effects,” Gary Matyas, Ph.D., chief of Adjuvants and Formulations for the U.S. Military Research Program (MHRP), WRAIR, said in a statement. “We hope to give people a window so they can overcome their addiction.”

The vaccine produced antibodies against other commonly misused opioids, including hydrocodone, oxycodone, hydromorphone, oxymorphone and codeine. The vaccine dampens the impact of heroin at a high-dose, indicating that it may have the potential to prevent overdoses.

In a clinical setting, the antibodies induced by a heroin or opioid vaccine do not cross-react with the therapies for opioid misuse, including methadone, buprenorphine and naltrexone.

However, the antibodies did not react with those compounds and the antibodies induced by the vaccine did not cross-react with naloxone, commonly used as the overdose rescue treatment to reverse respiratory depression due to heroin and other opioid overdose.

“Although we are still in the early phase, this study suggests that vaccination can be used together with standard therapies to prevent the withdrawal and craving symptoms associated with opioid withdrawal,” Matyas said.

The misuse of opioids including heroin and fentanyl, is an increasing problem in the U.S. According to the CDC, 91 Americans die every day from an opioid overdose. Most pharmacological treatments for opioid misuse involve opioid management therapy (OMT), but treatment access is an issue. Adherence varies greatly with relapse rates being high.

The vaccine was co-developed at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, which funded the preclinical research.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE